Showing 2191-2200 of 5623 results for "".
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- Théa Acquires Rights to KIO-301 for the Treatment of Inherited Retinal Diseases in $301 Million Dealhttps://modernod.com/news/thea-acquires-rights-to-kio-301-for-the-treatment-of-inherited-retinal-diseases-in-301-million-deal/2482089/Kiora Pharmaceuticals announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister company of Laboratoires Théa under with Kiora granted Théa exclusive worldwide development and commercialization rig
- Mireca Medicines Awarded Nearly $1 Million from the Foundation Fighting Blindness to Develop Treatments for IRDshttps://modernod.com/news/mireca-medicines-awarded-nearly-1-million-from-the-foundation-fighting-blindness-to-develop-treatments-for-inherited-retinal-diseases/2482085/Mireca Medicines announced it has received a $989,000 'Translational Research Acceleration Program Award' from Foundation Fighting Blindness that will permit the company to further advance the preclinical development of its lead product MM238. In a news
- Coherus Divest Ophthalmology Franchise to Sandoz in $170 Million Dealhttps://modernod.com/news/coherus-divest-ophthalmology-franchise-to-sandoz-in-170-million-deal/2482075/In a move to pay down debt and focus on its oncology business, Coherus BioSciences has entered into an agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for $170 million in cash, plus Cimerli inventory costs. This divestiture includes Co
- Regenxbio Announces Interim Data from Phase 2 AAVIATE Trial of ABBV-RGX-314 for Wet AMD Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-interim-data-from-phase-2-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery/2482066/Regenxbio announced positive interim data from the phase 2 AAVIATE trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) using suprachoroidal delivery. Investigational ABBV-RGX-314 is designed to be a one-time, in office treatment that has the potent
- Decision on the Adoption of a Sale Plan for Pixium Vision Postponedhttps://modernod.com/news/decision-on-the-adoption-of-a-sale-plan-for-pixium-vision-postponed/2482065/Pixium Vision announced that the decision of the Paris Commercial Court on the takeover offer filed on November 20, 2023 and the opening of judicial liquidation proceedings has been postponed to a later date, which will be communicated by the company as soon as it becomes aware of it.</
- OrCam Unveils Enhancements for MyEye and Read3 Devices at CEShttps://modernod.com/news/orcam-unveils-enhancements-for-myeye-and-read3-devices-at-ces/2482050/OrCam Technologies, which is focused on personal artificial intelligence (AI) assistive technology platforms, introduced new enhancements for its MyEye and Read3 devices at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada.
- Alimera Completes Recruitment for the Synchronicity Study Evaluating Yutiqhttps://modernod.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/Alimera Sciences announced that it has completed enrollment for the company’s Synchronicity study, a prospective, open-label clinical study evaluating the safety and efficacy of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic noninfectious uveitis
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- LSU Health Discovery May Open New Therapeutic Avenues for Degenerative Diseases of the Brain and Eyehttps://modernod.com/news/lsu-health-discovery-may-open-new-therapeutic-avenues-for-degenerative-diseases-of-the-brain-and-eye/2482034/Scientists at LSU Health New Orleans’ Neuroscience Center of Excellence have identified a new mechanism that regulates a protein key for cell survival. It appears to protect against the excessive oxidative stress that precedes the development of neurodegenerative diseases of the brain and e